New trial of investigational immunotherapy in men on active surveillance

There appears to be a high degree of confidence that Barvarian Nordic’s Prostvac will show positive results in the ongoing Phase III clinical trial in men with metastatic, castration-resistant prostate cancer. An early stage trial has now been initiated among men with much less advanced disease disease. … READ MORE …

Prostvac Phase III trial results in mCRPC “by early 2017”

According to a Reuters report issued early this morning, the CEO of Barvarian Nordic has stated publicly that the company expects results of Phase III trials of Prostvac VF in men with metastatic, castration-resistant prostate cancer (mCRPC) by early 2017 or perhaps earlier. … READ MORE …

Prostvac + ipilimumab shows promise in management of mCRPC

Results from a small trial of Barvarian Nordic’s investigational drug Prostvac — used in combination with Bristol-Myers Squibb’s ipilimumab (Yervoy) — appear to have shown relatively dramatic effects in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Prostvac-type vaccine therapy in progressive prostate cancer after first-line therapy

A study just published in European Urology has suggested that early therapy with Prostvac-type vaccines might have value in the management of men with a rising PSA after first-line therapy. … READ MORE …

mCRPC patients in UK can participate in Phase III trial of Prostvac VF

According to a story in the UK’s Daily Telegraph this morning, the British government has given approval for eligible patients in the UK to participate in the randomized, Phase III trial of Prostvac VF — a new form of immunotherapy being tested in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Small, Phase I combo trial suggests 3-year overall survival in men with mCRPC

A media release issued earlier today by Barvarian Nordic (the developer of Prostvac®) gives us an inkling of where we may be headed in the development of combination therapies for the management of late stage (and maybe even earlier stage) forms of prostate cancer. … READ MORE …

Barvarian Nordic starts multi-center, Phase III trial of Prostvac

Barvarian Nordic has initiated the expected, randomized, multi-center Phase III trial of Prostvac® in men with asymptomatic and minimally symptomatic, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …